35.15USDMkt Cap: 1.80B USDP/E: 81.74Last update: 2026-05-21
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.80B USD
Enterprise Value1.74B USD
Revenue (TTM)292.09M USD
Gross Profit205.60M USD
Net Income (TTM)16.52M USD
Revenue/Share5.777 USD
Last Price35.15 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees398
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92346J1088
Valuation
P/E (Trailing)81.74
P/E (Forward)41.26
PEG—
EV/EBITDA62.54
EV/Revenue5.97
P/S6.15
P/B5.03
EPS (TTM)0.43
EPS (Forward)0.85
52W Range
34.6330% of range36.35
52W High36.35 USD
52W Low34.63 USD
Profitability
Gross Margin74.42%
Oper. Margin-11.79%
EBITDA Margin9.55%
Profit Margin5.98%
ROE4.66%
ROA3.39%
Growth
Revenue Growth30.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF51.91M USD
CapEx (TTM)27.16M USD
FCF Margin14.51%
FCF Yield2.36%
Net Debt-50.30M USD
Net Debt/EBITDA-1.80
Balance Sheet
Debt/Equity0.27
Current Ratio5.18
Quick Ratio4.62
Book Value/Sh6.984 USD
Cash/Share2.846 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 16, 2013
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)55.43 USD
Target Range42.00 USD – 70.00 USD
# Analysts7
Ownership
Shares Out.51.07M
Float50.43M
Insiders1.20%
Institutions111.18%
Short Interest
Short Ratio8.1d
Short % Float12.56%
Short % Out.9.75%
Shares Short4.98M
Short (prev mo.)5.38M
Technical
SMA 5033.78 (+4.0%)
SMA 20035.43 (-0.8%)
Beta1.16
S&P 52W Chg28.31%
Avg Vol (30d)644.13K
Avg Vol (10d)728.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—